The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biosimilar trastuzumab-dkst monotherapy versus trastuzumab monotherapy after combination therapy: Final overall survival (OS) from the phase III HERITAGE Trial.
 
Cornelius F. Waller
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Mylan; Roche; Teva
Travel, Accommodations, Expenses - Bristol-Myers Squibb; IPSEN
 
Aleksei Manikhas
No Relationships to Disclose
 
Eduardo J. Pennella
Employment - Mylan
Stock and Other Ownership Interests - Mylan
 
Igor Bondarenko
No Relationships to Disclose
 
Guzel Mukhametshina
No Relationships to Disclose
 
Maria Luisa Abesanis Tiambeng
No Relationships to Disclose
 
Charuwan Akewanlop
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Roche
 
Ihor Vynnychenko
No Relationships to Disclose
 
Virote Sriuranpong
No Relationships to Disclose
 
Sirshendu Ray
No Relationships to Disclose
 
Miguel Hernandez-Bronchud
No Relationships to Disclose
 
Jay Herson
No Relationships to Disclose
 
Joseph D. Parra
No Relationships to Disclose
 
Gia Nemsadze
No Relationships to Disclose
 
Unmesh Gopalakrishnan
Employment - Mylan
Stock and Other Ownership Interests - Mylan
 
Subramanian Loganathan
Employment - Biocon
Stock and Other Ownership Interests - Biocon
 
Rafael Muniz
Employment - Mylan
Stock and Other Ownership Interests - Mylan
 
Abhijit Barve
Employment - Mylan
Stock and Other Ownership Interests - Mylan
 
Hope S. Rugo
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi